{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T10:55:06Z","timestamp":1783076106058,"version":"3.54.6"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,7]],"date-time":"2022-01-07T00:00:00Z","timestamp":1641513600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000200","name":"United States Agency for International Development","doi-asserted-by":"publisher","award":["AID-OAA-A-15-00045"],"award-info":[{"award-number":["AID-OAA-A-15-00045"]}],"id":[{"id":"10.13039\/100000200","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.eclinm.2022.101273","type":"journal-article","created":{"date-parts":[[2022,1,29]],"date-time":"2022-01-29T11:23:53Z","timestamp":1643455433000},"page":"101273","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Contraceptive effectiveness, pharmacokinetics, and safety of Sayana\u00ae Press when injected every four months: a multicenter phase 3 trial"],"prefix":"10.1016","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1535-1076","authenticated-orcid":false,"given":"Jennifer","family":"Deese","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian","family":"Brache","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Bahamondes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abril","family":"Salinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aidelis","family":"Jorge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Nelio","family":"Veiga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael","family":"Fuchs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doug","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera","family":"Halpern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laneta","family":"Dorflinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eclinm.2022.101273_bib0001","unstructured":"United Nations. Department of Economic and Social Affairs, Population Division. Contraceptive use by method 2019: data booklet. 2019. https:\/\/www.un.org\/development\/desa\/pd\/sites\/www.un.org.development.desa.pd\/files\/files\/documents\/2020\/Jan\/un_2019_contraceptiveusebymethod_databooklet.pdf. Accessed 9 Jul 2021."},{"issue":"5 Pt 2","key":"10.1016\/j.eclinm.2022.101273_bib0002","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/S0002-9378(12)91813-X","article-title":"Long-acting injectable contraception with depot medroxyprogesterone acetate","volume":"170","author":"Kaunitz","year":"1994","journal-title":"Am J Obstet Gynecol"},{"issue":"2","key":"10.1016\/j.eclinm.2022.101273_bib0003","first-page":"110","article-title":"Long-acting hormonal contraception: assessing impact on bone density, weight, and mood","volume":"44","author":"Kaunitz","year":"1999","journal-title":"Int J Fertil Womens Med"},{"key":"10.1016\/j.eclinm.2022.101273_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.100800","article-title":"Weight change among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: findings from a randomised, multicentre, open-label trial","volume":"34","author":"Beksinska","year":"2021","journal-title":"EClinicalMedicine"},{"issue":"1","key":"10.1016\/j.eclinm.2022.101273_bib0005","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3109\/13625187.2014.951433","article-title":"Weight variation in users of depot-medroxyprogesterone acetate, the levonorgestrel-releasing intrauterine system and a copper intrauterine device for up to ten years of use","volume":"20","author":"Modesto","year":"2015","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"10.1016\/j.eclinm.2022.101273_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.contraception.2018.04.003","article-title":"Hyperinsulinemic-euglycemic clamp over the first year of use of depot-medroxyprogesterone acetate as a contraceptive","author":"Melhado-Kimura","year":"2018","journal-title":"Contraception"},{"issue":"2","key":"10.1016\/j.eclinm.2022.101273_bib0007","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.contraception.2009.07.008","article-title":"Variations in body mass index of users of depot-medroxyprogesterone acetate as a contraceptive","volume":"81","author":"Pantoja","year":"2010","journal-title":"Contraception"},{"key":"10.1016\/j.eclinm.2022.101273_bib0008","unstructured":"Pharmacia and Upjohn Co., Division of Pfizer Inc. Depo Provera CI (medroxyprogesterone acetate) injectable suspension 150mg\/1mL [prescribing information]. Revised October 2010."},{"issue":"4","key":"10.1016\/j.eclinm.2022.101273_bib0009","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.contraception.2004.06.011","article-title":"Contraceptive efficacy and safety of DMPA-SC","volume":"70","author":"Jain","year":"2004","journal-title":"Contraception"},{"issue":"1","key":"10.1016\/j.eclinm.2022.101273_bib0010","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.contraception.2009.02.005","article-title":"Subcutaneous DMPA vs. intramuscular DMPA: a 2-year randomized study of contraceptive efficacy and bone mineral density","volume":"80","author":"Kaunitz","year":"2009","journal-title":"Contraception"},{"issue":"3","key":"10.1016\/j.eclinm.2022.101273_bib0011","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.contraception.2017.12.003","article-title":"Is a lower-dose, subcutaneous contraceptive injectable containing depot medroxyprogesterone acetate likely to impact women's risk of HIV?","volume":"97","author":"Polis","year":"2018","journal-title":"Contraception"},{"key":"10.1016\/j.eclinm.2022.101273_bib0012","unstructured":"Pfizer, Inc. Collaboration Helps Broaden Access to Pfizer's Contraceptive, Sayana Press (Medroxyprogesterone Acetate), for Women in Some of the World's Poorest Countries. 2017. https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/collaboration_helps_broaden_access_to_pfizer_s_contraceptive_sayana_press_medroxyprogesterone_acetate_for_women_in_some_of_the_world_s_poorest_countries. Accessed 9 Jul 2021."},{"key":"10.1016\/j.eclinm.2022.101273_bib0013","unstructured":"International Council for Harmonisation. ICH E6: guideline for good clinical practice. 2016. https:\/\/database.ich.org\/sites\/default\/files\/E6_R2_Addendum.pdf. Accessed 9 Jul 2021."},{"key":"10.1016\/j.eclinm.2022.101273_bib0014","unstructured":"PATH. Sayana Press injection job aid for providers. 2013. https:\/\/path.azureedge.net\/media\/documents\/RH_sp_training_jobaids_providers.pdf. Accessed 9 Jul 2021."},{"key":"10.1016\/j.eclinm.2022.101273_bib0015","unstructured":"Medicines and Healthcare Products Regulatory Agency (MHRA). Depo-subQ provera 104\u00ae medroxyprogesterone acetate injectable suspension 104mg\/0.65mL [public assessment report]. 2015."},{"key":"10.1016\/j.eclinm.2022.101273_bib0016","unstructured":"U.S. Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infections Diseases, Division of AIDS (DAIDS). Table for grading the severity of adult and pediatric adverse events, Corrected Version 2.1.; 2017."},{"key":"10.1016\/j.eclinm.2022.101273_bib0017","unstructured":"European Medicines Agency. Guideline on clinical investigation of steroid contraceptives in women. 2005. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-clinical-investigation-steroid-contraceptives-women_en.pdf. Accessed 9 Jul 2021."},{"key":"10.1016\/j.eclinm.2022.101273_bib0018","article-title":"Division of Pfizer Inc. Depo-subQ provera 104\u00ae medroxyprogesterone acetate injectable suspension 104mg\/0.65mL [package insert]","author":"Pharmacia","year":"2015","journal-title":"Revised"},{"issue":"1","key":"10.1016\/j.eclinm.2022.101273_bib0019","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1210\/jcem-44-1-32","article-title":"Serum medroxyprogesterone acetate (MPA) concentrations and ovarian function following intramuscular injection of depo-MPA","volume":"44","author":"Ortiz","year":"1977","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.eclinm.2022.101273_bib0020","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.contraception.2013.07.002","article-title":"Pharmacokinetics of subcutaneous depot medroxyprogesterone acetate injected in the upper arm","volume":"89","author":"Halpern","year":"2014","journal-title":"Contraception"},{"key":"10.1016\/j.eclinm.2022.101273_bib0021","unstructured":"NCT04893798. A study comparing subcutaneous injection of sayana press in the upper arm versus anterior thigh and abdomen. 20 May 2021. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04893798. Accessed 9 July 2021."},{"key":"10.1016\/j.eclinm.2022.101273_bib0022","unstructured":"European Medicines Agency. SAYANA PRESS 104mg\/0.65ml suspension for injection. Summary of product characteristics. 2 Sept 2020. https:\/\/www.medicines.org.uk\/emc\/product\/3148\/smpc#gref. Accessed 9 Jul 2021."},{"key":"10.1016\/j.eclinm.2022.101273_bib0023","unstructured":"World Health Organization. Selected practice recommendations for contraceptive use, Third edition. 2016. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/252267\/9789241565400-eng.pdf;jsessionid=6694CD0E01A22728DFD7C89D24550918?sequence=1. Accessed 7 Jul 2021."}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537022000037?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537022000037?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T19:11:57Z","timestamp":1762888317000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537022000037"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":23,"alternative-id":["S2589537022000037"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2022.101273","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Contraceptive effectiveness, pharmacokinetics, and safety of Sayana\u00ae Press when injected every four months: a multicenter phase 3 trial","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2022.101273","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101273"}}